The aim of the proposal is the evaluation of the safety profiles of biological therapies in asthma and the elaboration of recommendations for the prevention and management of adverse reactions to biologics in asthma.

There is a strong need for a comprehensive, comparative review of the safety profiles of biologicals as these represent different mechanisms of action, and the growing body of evidence suggests pleiotropic effects of the treatments at the molecular, cellular, and tissue levels, beyond those described in the respective pivotal trials. Accordingly, a growing body of evidence suggests substantial differences in the safety profiles between these drugs.

Based on the systematic reviews performed for the “EAACI Biologicals Guidelines – Recommendations for severe asthma”, data will be extracted and analyzed. The expert panel will review the existing and gathered evidence and formulate recommendations, which will address broad prevention measures as well as proper management of these reactions. A position paper on adverse reactions to biologics per class will be performed and published in Allergy to support the decision-making process for the HCP.